Cyto-Pathology Classification

Diagnosis
Myelodysplastic syndrome -subtype refractory anemia cytopenia with multilineage dysplasia (MDS -RCMD) according to the WHO classification.
Survival
Date of diagnosis: 03-2008
Treatment: Allogeneic stem cell transplantation from an HLA-mismatched unrelated donor as first-line strategy (peripheral stem cell transplantation; PBSCT) after a dose reduced conditioning regimen (fludarabine, amsacrine, cytarabine, busulfane) in combination with thymoglobuline. Other molecular cytogenetics technics: See figure below: Fluorescence in situ hybridization with probes flanking the breakpoints within the ETV6 gene demonstrating an ETV6 rearrangement (left) and in a second hybridization with whole chromosome painting probes for chromosome 1 (red) and chromosome 12 (green) on the same metaphase.
A Case of Myelodysplastic Syndrome with a Translocation t(1;12)(p36;p13)
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Other molecular cytogenetics results:
No evidence of the FLT3-ITD/LM (internal tandem duplication/length mutation), NRAS-mutation, or MLL-PTD (partial tandem duplication) by polymerase chain reaction (PCR) analyses.
Comments
Two our knowledge so far two cases with a t(1;12)(p36;p13) were described in the literature. The first reported case suffered from chronic myeloid leukemia (CML) (Vassallo et al., 1993) . The second patient, a 66-old female, showed MDS in transformation (RAEB-T) and rapidly proceeded to secondary acute myeloid leukemia (AML) (Oedro et al., 2002) . The here reported case -a 46 year old malehad MDS in an initial stage (RCMD). Treatment was performed by upfront allogeneic stem cell transplantation unfortunately followed by severe complications with hemolysis and intestinal bleeding resulting in early transplant-associated mortality. So far, the prognostic impact of the t(1;12)(p36;p13)/ETV6-TEL cannot be determined. As the respective translocation is difficult to detect in chromosome banding analyses, the true frequency might be higher than actually thought. Call for Collaborations PD Dr. med. Claudia Haferlach MLL, Munich Leukemia Laboratory, Max-LebschePlatz 31, 81377 Munich, Germany Claudia.haferlach@mll-online.com
